Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Silence Therapeutics plc | EVP and Chief R&D Officer | Employee Share Option (Right to Buy) | 285K | Jan 2, 2025 | Direct | ||
Dianthus Therapeutics, Inc. /DE/ | Director | Stock Option (Right to Buy) | 22K | Sep 16, 2024 | Direct | ||
Silence Therapeutics plc | EVP and Chief R&D Officer | Ordinary Shares | 13K | Jan 2, 2025 | Direct | ||
Mallinckrodt plc | EVP & Chief Sci. Ofcr | Ordinary Shares | 0 | $37.50 | Jun 16, 2022 | Direct | |
Mallinckrodt plc | EVP & Chief Sci. Ofcr | Employee Share Options (Right to Buy) | 0 | Jun 16, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SLN | Silence Therapeutics plc | Jan 2, 2025 | 1 | $0 | 4 | Jan 6, 2025 | EVP and Chief R&D Officer |
SLN | Silence Therapeutics plc | Jan 2, 2025 | 0 | $0 | 3 | Jan 2, 2025 | EVP and Chief R&D Officer |
DNTH | Dianthus Therapeutics, Inc. /DE/ | Sep 16, 2024 | 1 | $0 | 4 | Sep 18, 2024 | Director |
DNTH | Dianthus Therapeutics, Inc. /DE/ | Sep 16, 2024 | 0 | $0 | 3 | Sep 18, 2024 | Director |
MNKPF | Mallinckrodt plc | Jun 16, 2022 | 7 | $0 | 4 | Jun 21, 2022 | EVP & Chief Sci. Ofcr |